Anti-infective vaccine market is expected to grow at constant state, which is likely to amount USD 64,317.8 million in the year 2025 and estimated to grow at CAGR of 11.8%, at USD 196,222.0 million by the year 2035. One such foremost driving factor behind the growth is the increasing rate of infectious disease and the increasing need for vaccination program worldwide. The anti-infective vaccines avert a lot of infectious diseases caused by bacteria, viruses, fungus and parasites.
They play vital roles in the reduction of disease burden and are useful to the promotion of public health, which has led to extensive uptake across the world. The market growth is also driven by advances in vaccine technology, such as the emergence of mRNA-based vaccines and new delivery systems that enhance the efficacy and accessibility of vaccines.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2024E) | USD 64,317.8 million |
| Market Value (2031F) | USD 196,222.0 million |
| CAGR (2025 to 2035) | 11.8% |
The market for anti-infective vaccines is fragmented and several companies are present globally and in North America will hold a significant market share. The growth of infectious diseases, particularly respiratory and vector-borne diseases, is one of the major drivers for the anti-infective vaccines market in this region.
In addition, the existence of strong healthcare infrastructure, access to sophisticated diagnostic equipment, and high levels of awareness between healthcare professionals and patients regarding the need for vaccination also serve to be market drivers to growth in the region. Moreover, rising adoption of preventive healthcare and enhanced government programs toward different immunization programs add weight to the market growth of the anti-infective vaccines in the region.
The anti-infective vaccines market in Europe is expected to grow owing to a well-developed healthcare infrastructure coupled with growing awareness towards disease prevention in population. Germany, France and the United Kingdom will be some of the early adopters of sophisticated vaccines because they have strong healthcare systems and focus on prevention. The key factors driving this growth include significant investments in vaccine research and development across the region, as well as an increasing incidence of infectious diseases.
Moreover, the policies of European Union make it possible to establish immunization system for disease control, consequently increasing the vaccination awareness and access to vaccines, which boost the market demand for anti-infective vaccines. The rising emphasis on preventing pathogens transmission to reduce healthcare expenditures and improve patient outcomes, is expected to further augment the European anti-infective vaccines market.
The Asia-Pacific region is anticipated to undergo a tremendous growth in the anti-infective vaccines market due to improved access to healthcare and high awareness for immunization. Countries like China, India, and Japan are witnessing the growing consumption of vaccines due to government policy support, enhanced healthcare facilities, and a growth in the patient base.
Growing infectious disease burden and increasing healthcare expenditure is projected to drive the demand for low-cost vaccines in countries like India and China. In addition, the growing establishment of rural health care centers and availability of low-priced health care are also anticipated to augment the market. With increased use of modern vaccine technologies by ASEAN and other Asia-Pacific point-of-care (POC) healthcare providers, Asia-Pacific has become one of the key contributors to the high growth of anti-infective vaccines market.
Regulatory Compliance and Cost Constraints
The high related costs with vaccine formulation and circulation along with strict regulations are few deterrents to the growth of anti-infective vaccines market. These will hamper market growth, especially in low- and middle-income countries, due to affordability issues. The market entry of manufacturers has to abide by safety and efficacy standards, which can lead to a prolonged approval process through various regions, making it more expensive to produce. Competition from more cost-competitive vaccines may also threaten market growth in developing countries.
Technological Advancements and Global Immunization Initiatives
Innovations within vaccine platforms, such as mRNA-base vaccines and newer adjuvants have enabled more (restrictive) use of anti-infective vaccines. Such innovations enable enhanced protection against a wider spectrum of pathogens, lowering the risk of disease outbreaks, thereby improving global health outcomes.
Furthermore, increasing global immunization programs and growing investments for the development of vaccines offer immense growth opportunities for the players operating in the market. As more emphasis is placed on preventive healthcare (i.e. regular check-ups) and disease elimination programs, the market for anti-infective vaccines as public health tools is ever expanding.
| Market Shift | 2020 to 2024 |
|---|---|
| Vaccine Development | Focus on traditional vaccine platforms |
| Regulatory Environment | Moderate focus on standardization |
| Market Expansion | Growth driven by regional immunization programs |
| Consumer Preferences | Preference for established vaccines |
| Market Shift | 2025 to 2035 |
|---|---|
| Vaccine Development | Shift towards mRNA and next-generation vaccine technologies |
| Regulatory Environment | Increased emphasis on global harmonization and compliance |
| Market Expansion | Expansion fueled by global health initiatives and funding |
| Consumer Preferences | Growing demand for innovative and more effective vaccine solutions |
Concern over infectious diseases, both endemic and emerging, is playing a major role in driving demand for anti-infective vaccines. The drivers also include the growing government initiatives towards vaccination programs, public health awareness campaigns, and technology advancements in vaccine are also supporting the growth of the market.
In the USA, further contributions in CV are expected demonstrating considerable investments in R&D of unique vaccine formats that provide efficacy against broad infectious disease targets including respiratory infections, influenza and other emerging pathogens. The market growth is further boosting by due to strong healthcare infrastructure and widespread acceptance of vaccination.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 11.8% |
Over the forecast period, the UK anti-infective vaccines market is expected to rise at a CAGR of 12.2%. The growth of the market is due to the good health infrastructure in the world and the preventive strategy of the kingdom for infectious diseases based on vaccination programs. Recent global health challenges have underscored the importance of sustained innovation in vaccine use, focusing on the elderly, immunocompromised individuals, and other at-risk populations.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 12.2% |
The European Market for anti-infective vaccines is expected to grow at a CAGR of 11.9% till 2035. Few trends driving demand in the vaccines market in countries such as Germany, France, and Italy are the frequent rise in infectious disease outbreaks and growing emphasis on public health initiatives.
The European Union's joint initiatives in vaccination programs and funding innovative vaccine research strengthen the market growth. Furthermore, the movement towards personalized vaccines developed for certain populations and diseases is expected to drive tremendous growth in the region.
| Region | CAGR (2025 to 2035) |
|---|---|
| Europe an Union | 11.9% |
Japan’s anti-infective vaccines market is anticipated to grow at a CAGR of 11.5% over the forecast period. One of the other thing driving the market possible is the health system which focuses on preventive medicine and vaccination. Growing awareness of infectious disease spread and Japan’s aging population are encouraging uptake of vaccines. Ongoing governmental support for vaccination programs and new vaccine technology research will continue to drive growth in the market, especially in the areas of respiratory and seasonal disease prevention.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 11.5% |
Anti-Infective vaccines market expected to grow in South Korea with a CAGR of 12.0%. Market growth has been significantly driven by enhanced vaccine development capacities as well as robust government health policies encouraging vaccinations over the past several years. Intensified emphasis on infectious diseases such as influenza and pneumonia-related diseases has raised the bar for vaccines. South Korea's developments in biopharmaceuticals technology and vaccine manufacturing capacity make it a frontrunner in regional vaccine development.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 12.0% |
| By Type | Market Share (2025) |
|---|---|
| Inactivated Vaccines | 46.3% |
The largest share of the anti-infective vaccines market is accounted for by inactivated vaccines, where it constitutes 46.3% in 2025. These vaccines consist of pathogens that are dead or inactive so as not to cause disease while still stimulating a vigorous immune response. They have a better safety profile than most drugs and thus should be suitable for use in immunocompromised individuals, infants and the elderly.
Inactivated vaccines thus are more stable and a priori less likely to revert to virulence than live attenuated vaccines. They are easy to store and transport, which is important for global immunization programs, especially in developing areas. In addition, public health agencies as well as international have often favoured inactivated for mass immunization campaigns their lower complication rates and ease of storage conditions make them more manageable.
Due to ongoing improvements in both vaccine formulation and adjuvant technologies, inactivated vaccines show greater immunogenicity and sustained protection. Considering their ability against bacterial as well as viral targets, they persist with high demand in both routine immunization schedules and epidemic response activities, thereby preserving their market domination.
| By Application | Market Share (2025) |
|---|---|
| Viral Diseases | 58.6% |
In 2025, it also will have the largest market segment share 58.6% due to global level prioritization towards prevention, control, treatment of widespread and high burden of infectious diseases especially viral diseases. Vaccineable viral pathogens such as hepatitis B, influenza, human papillomavirus (HPV) and measles are among the anti-infective vaccines most widely used around the world. Given the ongoing risk of pandemics and outbreaks, the demand for widespread vaccination against viral diseases is growing.
Vaccination is the most effective way to prevent morbidity and mortality caused by viral infections. With vaccination of viral diseases, governments and global health organizations are increasingly backing up through support of funding and sharing of infrastructure and ultimately leading to widespread adoption of viral disease vaccines. Viral mutations and the emergence of novel strains constantly fuel R&D, resulting in innovation and market expansion.
The systematic administration of childhood and adolescent vaccines through school-based and age-based immunization programs is also an asset for the segment. The advances in vaccine platforms such as mRNA and viral vectors and nanoparticle-based delivery will help expedite development of targeted and next-generation vaccines against viruses thus further fortifying the growth of this segment.
The global anti-infective vaccines market is expected to witness remarkable growth in the near future owing to increasing technological advancements for different type of vaccines, increasing number of government programs, and increasing awareness towards various health related diseases.
The new vaccinology and adjunctive vaccinology are reinforcing the efficacy and safety features of vaccines, while new technologies such as mRNA, recombinant protein vaccines and adjuvants enable faster development time and a more responsive manner to manufacture against contagious diseases. The market is also being driven by the expansion of delivery and research initiatives with government investment and public health programs.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| GlaxoSmithKline (GSK) | 20-25% |
| Sanofi | 15-20% |
| Merck & Co. | 12-15% |
| Pfizer Inc. | 10-12% |
| Other Companies (combined) | 28-43% |
| Company Name | Key Offerings/Activities |
|---|---|
| GlaxoSmithKline (GSK) | In 2024, launched a new pneumococcal vaccine, Arexvy, targeting respiratory syncytial virus (RSV) and herpes zoster. |
| Sanofi | In 2025, introduced a novel conjugate vaccine for meningococcal disease, offering broader protection against multiple serogroups. |
| Merck & Co. | In 2024, received FDA approval for Capvaxive, a pneumococcal vaccine targeting 21 bacterial strains, designed for adults over 50. |
| Pfizer Inc. | In 2025, expanded its Prevnar 20 vaccine to include additional serotypes, enhancing coverage against pneumococcal diseases. |
| Moderna Inc. | In 2024, initiated clinical trials for an mRNA-based vaccine targeting influenza and respiratory syncytial virus (RSV). |
| Novavax Inc. | In 2025, developed a protein-based vaccine for malaria, entering new therapeutic areas beyond respiratory infections. |
Key Company Insights
GlaxoSmithKline (GSK) (20-25%)
GSK is a market leader with its comprehensive vaccine portfolio, including the recently launched Arexvy for RSV and Shingrix for herpes zoster. Despite recent sales challenges, GSK remains optimistic about future growth through global expansion and stable market share.
Sanofi (15-20%)
Sanofi focuses on developing vaccines for various infectious diseases, with recent advancements in meningococcal vaccines. The company's strong R&D pipeline positions it as a significant player in the anti-infective vaccines market.
Merck & Co. (12-15%)
Merck's approval of Capvaxive, a pneumococcal vaccine targeting 21 strains, positions it to challenge Pfizer's Prevnar 20. The company's focus on broad-spectrum vaccines enhances its competitive edge in the market.
Pfizer Inc. (10-12%)
Pfizer continues to lead the pneumococcal vaccine market with Prevnar 20. The company's ongoing efforts to expand vaccine coverage and its strong global distribution network contribute to its market dominance.
Moderna Inc. (Emerging Player)
Moderna is leveraging its mRNA technology to develop vaccines for influenza and RSV, showcasing its potential to revolutionize vaccine development and address unmet medical needs.
Novavax Inc. (Emerging Player)
Novavax is expanding its vaccine portfolio beyond respiratory infections, with the development of a protein-based malaria vaccine, indicating its commitment to addressing a broader range of infectious diseases.
The anti-infective vaccines market size in 2025 was USD 64,317.8 million.
Anti-infective vaccines market is projected to reach USD 196,222.0 million.
Key growth drivers include rising prevalence of infectious diseases, strong government immunization initiatives and global demand for pandemic preparedness.
The top contributors are USA, UK, Europe, JapanS and South Korea.
The viral diseases segment is anticipated to dominate.
Explore Therapy Area Insights
Anti-Infective Vaccines Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
